Sam Brusco, Associate Editor07.21.22
RapidAI has earned U.S. Food and Drug Administration (FDA) clearance for Rapid Hyperdensity.
The tool allows quick assessment of injury severity in patients with acute neuro conditions like traumatic brain injury and brain hemorrhages.
Rapid Hyperdensity uses non-contrast CT scans to assess volume of hyperdense tissue in the brain, helping identify the extent of an intracerebral hemorrhage. It provides additional contextual data for hospitals and mobile stroke units so more informed triage and transfer decisions can be made.
“Rapid Hyperdensity helps physicians make the first of many critical decisions involved in head trauma and hemorrhagic stroke protocol. As the only comprehensive neurovascular decision support platform to offer this functionality, RapidAI aims to alleviate the enormous pressure of determining the best next course of action,” Karim Karti, CEO of RapidAI told the press. “This FDA clearance is a symbol of RapidAI’s ongoing commitment to push the boundaries of neurovascular care, while designing every product with physicians first in mind.”
Rapid Hyperdensity can automatically detect intracranial hyperdensities >1ml. Hyperdense volumes are quickly identified to improve hemorrhage management. The results can be viewed on the Rapid mobile app, PACS/Workstation, or email.
"As a neurosurgeon who treats many patients with intracranial hemorrhage (ICH), I am very excited for the recently approved Rapid Hyperdensity product that builds on the well-established RapidAI stroke platform,” said Dr. Alejandro M. Spiotta, director of the Neuroendovascular Surgery Division at the Medical University of South Carolina. “Detection of ICH via AI can save lives by helping to speed up diagnosis and accelerate transfer to the best physician and hospital that can take care of the patient. With the addition of automatic hyperdense volume measurement, physicians can more easily track volume over time and help quickly identify which patients may require an intervention. This is an exciting time for those of us treating ICH."
The tool allows quick assessment of injury severity in patients with acute neuro conditions like traumatic brain injury and brain hemorrhages.
Rapid Hyperdensity uses non-contrast CT scans to assess volume of hyperdense tissue in the brain, helping identify the extent of an intracerebral hemorrhage. It provides additional contextual data for hospitals and mobile stroke units so more informed triage and transfer decisions can be made.
“Rapid Hyperdensity helps physicians make the first of many critical decisions involved in head trauma and hemorrhagic stroke protocol. As the only comprehensive neurovascular decision support platform to offer this functionality, RapidAI aims to alleviate the enormous pressure of determining the best next course of action,” Karim Karti, CEO of RapidAI told the press. “This FDA clearance is a symbol of RapidAI’s ongoing commitment to push the boundaries of neurovascular care, while designing every product with physicians first in mind.”
Rapid Hyperdensity can automatically detect intracranial hyperdensities >1ml. Hyperdense volumes are quickly identified to improve hemorrhage management. The results can be viewed on the Rapid mobile app, PACS/Workstation, or email.
"As a neurosurgeon who treats many patients with intracranial hemorrhage (ICH), I am very excited for the recently approved Rapid Hyperdensity product that builds on the well-established RapidAI stroke platform,” said Dr. Alejandro M. Spiotta, director of the Neuroendovascular Surgery Division at the Medical University of South Carolina. “Detection of ICH via AI can save lives by helping to speed up diagnosis and accelerate transfer to the best physician and hospital that can take care of the patient. With the addition of automatic hyperdense volume measurement, physicians can more easily track volume over time and help quickly identify which patients may require an intervention. This is an exciting time for those of us treating ICH."